Seed · Healthtech
Retham Technologies raises $1.5m seed for clinical validation
HITDx uses cryopreserved donor platelets to support practical functional testing in hospital laboratories.
Retham plans to advance HITDx through clinical validation, pursue FDA 510(k) clearance and prepare for commercialization.
The diagnostic remains in validation and regulatory development. Its stable cryopreserved donor platelets are separately available for research use, distinct from clearance of HITDx as a clinical assay.
Use of funds
Advance HITDx through clinical validation
Pursue FDA 510(k) clearance
Prepare for commercialization
Funding history
Seed · This round$1.5M